UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000062021
Receipt number R000070972
Scientific Title Evaluation of the effects of continuous use of test products on skin condition
Date of disclosure of the study information 2026/06/23
Last modified on 2026/06/23 11:02:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the effects of continuous use of test products on skin condition

Acronym

Evaluation of the effects of continuous use of test products on skin condition

Scientific Title

Evaluation of the effects of continuous use of test products on skin condition

Scientific Title:Acronym

Evaluation of the effects of continuous use of test products on skin condition

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of continuous use of test products on skin condition

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Changes in skin condition parameters following intervention (measured values and images)

Key secondary outcomes

Changes in skin condition parameters following intervention (absolute changes and percentage changes)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Continuous use of the test products

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

22 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1. Men or women
2. Adults (aged 22 to 59)
3. Healthy individuals

Key exclusion criteria

1. Individuals with severe skin conditions, such as dermatitis
2. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
3. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)
4. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, metabolic bone disorders, including osteoporosis and fractures, or any other chronic diseases
5. Individuals who are unable to avoid intentional sun exposure, such as sunbathing, during the study period
6. Individuals with known allergies to medications or test-related substances
7. Individuals who have a present condition or have a medical history of drug or alcohol dependence
8. Individuals who are pregnant, lactating, or planning to become pregnant during this study
9. Individuals who currently or within the past month have a habit of continuous oral intake or topical application of drugs claiming skin improvement benefits, or who are otherwise judged by the principal investigator to be inappropriate for this study
10. Individuals who are using cosmetics with strong moisturizing or anti-wrinkle effects
11. Individuals who are judged as ineligible to participate in this study by the physician

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Kazuya
Middle name
Last name Watabe

Organization

Pharma Foods International Co., Ltd.

Division name

R&D Department

Zip code

615-8245

Address

1-49, Goryohara, Nishikyo-ku, Kyoto-shi, Kyoto, Japan

TEL

075-748-9829

Email

watabe@pharmafoods.co.jp


Public contact

Name of contact person

1st name Saki
Middle name
Last name Shirako

Organization

Pharma Foods International Co., Ltd.

Division name

R&D Department

Zip code

615-8245

Address

1-49, Goryohara, Nishikyo-ku, Kyoto-shi, Kyoto, Japan

TEL

075-748-9829

Homepage URL


Email

saki-shirako@pharmafoods.co.jp


Sponsor or person

Institute

Pharma Foods International Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Client

Organization

Division

Category of Funding Organization

Outside Japan

Nationality of Funding Organization

Thailand


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation DiaStep Ouchinodoctor Research Ethics Committee

Address

Morizumi Bldg. 3F, 4-22-7 Taishido, Setagaya-ku, Tokyo, 154-0004, Japan

Tel

03-5433-3255

Email

tomohisa.kato@diastep.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

株式会社ファーマフーズ (京都府)


Other administrative information

Date of disclosure of the study information

2026 Year 06 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2026 Year 06 Month 10 Day

Date of IRB

2026 Year 06 Month 19 Day

Anticipated trial start date

2026 Year 06 Month 25 Day

Last follow-up date

2026 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 06 Month 23 Day

Last modified on

2026 Year 06 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070972